Anti-CD38/ ADPRC 1/ ADPRC1 monoclonal antibody
Anti-CD38/ ADPRC 1/ ADPRC1 antibody for FACS & in-vivo assay
Go to CD38/CD38 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T10877-Ab-1/ GM-Tg-hg-T10877-Ab-2 | Anti-Human CD38 monoclonal antibody | Human |
GM-Tg-rg-T10877-Ab-1/ GM-Tg-rg-T10877-Ab-2 | Anti-Rat CD38 monoclonal antibody | Rat |
GM-Tg-mg-T10877-Ab-1/ GM-Tg-mg-T10877-Ab-2 | Anti-Mouse CD38 monoclonal antibody | Mouse |
GM-Tg-cynog-T10877-Ab-1/ GM-Tg-cynog-T10877-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD38 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T10877-Ab-1/ GM-Tg-felg-T10877-Ab-2 | Anti-Feline CD38 monoclonal antibody | Feline |
GM-Tg-cang-T10877-Ab-1/ GM-Tg-cang-T10877-Ab-2 | Anti-Canine CD38 monoclonal antibody | Canine |
GM-Tg-bovg-T10877-Ab-1/ GM-Tg-bovg-T10877-Ab-2 | Anti-Bovine CD38 monoclonal antibody | Bovine |
GM-Tg-equg-T10877-Ab-1/ GM-Tg-equg-T10877-Ab-2 | Anti-Equine CD38 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T10877-Ab-1/ GM-Tg-hg-T10877-Ab-2; GM-Tg-rg-T10877-Ab-1/ GM-Tg-rg-T10877-Ab-2; GM-Tg-mg-T10877-Ab-1/ GM-Tg-mg-T10877-Ab-2; GM-Tg-cynog-T10877-Ab-1/ GM-Tg-cynog-T10877-Ab-2; GM-Tg-felg-T10877-Ab-1/ GM-Tg-felg-T10877-Ab-2; GM-Tg-cang-T10877-Ab-1/ GM-Tg-cang-T10877-Ab-2; GM-Tg-bovg-T10877-Ab-1/ GM-Tg-bovg-T10877-Ab-2; GM-Tg-equg-T10877-Ab-1/ GM-Tg-equg-T10877-Ab-2 |
Products Name | Anti-CD38 monoclonal antibody |
Format | mab |
Target Name | CD38 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CD38 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T10877 |
Target Name | CD38 |
Gene ID | 952,12494,25668,714399,403756,101101308,327677,100068959 |
Gene Symbol and Synonyms | ADPRC 1,ADPRC1,cADPR1,CD38,Cd38-rs1,I-19 |
Uniprot Accession | P28907,Q64244 |
Uniprot Entry Name | CD38_HUMAN,CD38_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | Cancer |
Gene Ensembl | ENSG00000004468 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: CD38, gene name: CD38, also named as ADPRC 1, ADPRC1. The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.